Sep. 30 at 8:03 PM
$IMRX (1) In June 2024,
$SNY invested US
$40 million in Vigil via a private placement / strategic investment including rights like the exclusive right of first negotiation for Vigil’s TREM2 small molecule program. In May 2025, Sanofi entered a definitive merger agreement to acquire Vigil for ~
$470 million.
(2) Sanofi made an equity investment of US
$35 million in early 2023, under a securities purchase agreement tied to a co-promotion agreement for
$PRVB 's drug (Tzield / teplizumab). In March/April 2023, Sanofi acquired Provention Bio for about US
$2.9 billion in cash.
(3) And now Sanofi has agreed to purchase 2,708,559 shares of Immuneering’s Class A common stock, at a purchase price of
$9.23 per share, equal to US
$25 million, in a separate private placement transaction. Question is: when Sanofi buys IMRX outright and for how much?
